Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

All Drugs Associated with Second primary malignancy (Page 3)

237 drugs have been associated with Second primary malignancy in FAERS reports.

Drug Reports Deaths Hosp. Life-Threat.
LAPATINIB 27 22 0 2
MESNA 26 7 3 1
VINDESINE 26 12 4 3
IBRITUMOMAB TIUXETAN 25 11 1 0
PAMIDRONATE 25 2 4 0
PERTUZUMAB 25 15 22 1
CYCLOSPORINE 24 14 7 2
OLANZAPINE 24 0 14 23
VENETOCLAX 24 4 2 1
DENOSUMAB 23 0 5 0
LUTETIUM OXODOTREOTIDE LU-177 23 4 8 4
TOPOTECAN 23 6 8 4
GRANULOCYTE COLONY-STIMULATING FACTOR NOS 22 8 1 1
RAMIPRIL 22 3 19 0
TOSITUMOMAB I-131 22 21 0 0
DOCETAXEL\DOCETAXEL ANHYDROUS 21 0 8 1
METFORMIN 21 0 8 1
THIOGUANINE 21 10 8 2
APIXABAN 20 18 19 19
ALPELISIB 19 2 4 1
ERIBULIN 19 1 1 0
ALEMTUZUMAB 18 11 0 0
INOTUZUMAB OZOGAMICIN 18 9 7 7
LAPATINIB DITOSYLATE 18 6 4 0
MYCOPHENOLATE MOFETIL 18 12 5 3
PIPERACILLIN\TAZOBACTAM 18 18 18 18
CELECOXIB 17 16 11 0
MIDOSTAURIN 17 3 3 2
DEFERASIROX 16 9 12 5
PANTOPRAZOLE 16 13 13 0
POLATUZUMAB VEDOTIN 16 4 2 0
POMALIDOMIDE 16 3 4 1
SUTENT 16 5 4 1
TASIGNA 16 2 4 1
ATORVASTATIN 15 2 1 0
CERITINIB 15 3 5 1
LEUCOVORIN\LEUCOVORIN 15 9 2 2
PONATINIB 15 2 6 0
VALSARTAN 15 11 13 0
ATEZOLIZUMAB 14 4 4 2
ETANERCEPT 14 4 7 5
GEMCITABINE\GEMCITABINE 14 5 3 1
TACROLIMUS 14 7 2 2
ADO-TRASTUZUMAB EMTANSINE 13 1 2 0
ARSENIC TRIOXIDE 13 0 0 2
CLOZAPINE 13 1 10 5
PEGASPARGASE 13 7 10 4
RABEPRAZOLE 13 4 9 2
THIOGUANINE ANHYDROUS 13 9 8 0
THYMOCYTE IMMUNE GLOBULIN NOS 13 11 0 1
« 1 2 3 4 5 »